Annual report pursuant to Section 13 and 15(d)

Note 11 - Related party transactions (Details Textual)

v3.24.1
Note 11 - Related party transactions (Details Textual) - USD ($)
 12 Months Ended 26 Months Ended
Sep. 06, 2023
Nov. 04, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Mar. 26, 2024
Jan. 31, 2024
Aug. 10, 2023
Schedule of Equity Method Investments [Line Items]                
Accrued liabilities     $ 8,829,000 $ 5,085,000 $ 8,829,000      
Accounts payable     3,492,000 3,342,000 3,492,000      
Tuspetinib Licensing Agreement [Member]                
Schedule of Equity Method Investments [Line Items]                
License Fee, Total   $ 12,500,000            
Payments for License Fee   5,000,000            
Stock Issued During Period, Value, Licensing Fee   $ 7,500,000            
Supply Agreement [Member]                
Schedule of Equity Method Investments [Line Items]                
Expenses     $ 3,500,000 3,600,000 7,100,000      
Payment of supply costs         $ 4,500,000      
Accrued liabilities       600,000        
Accounts payable       3,000,000        
Hanmi Pharmaceuticals Co Ltd [Member]                
Schedule of Equity Method Investments [Line Items]                
Number of common shares held   215,703 884,152   884,152      
Future milestone payments   $ 407,500,000            
Gross proceeds of sale stock $ 3,000,000   $ 3,000,000          
Payment of supply costs     4,500,000 $ 0        
Hanmi Pharmaceuticals Co Ltd [Member] | Subsequent Event [Member]                
Schedule of Equity Method Investments [Line Items]                
Warrants to purchase common shares, number of warrants           2,339,181 2,339,181  
Warrants to purchase common shares, exchange price           $ 1.71 $ 1.71  
Hanmi Pharmaceuticals Co Ltd [Member] | Common Shares [Member]                
Schedule of Equity Method Investments [Line Items]                
Number of shares sold 668,449              
Hanmi Pharmaceuticals Co Ltd [Member] | Common Shares [Member] | Subsequent Event [Member]                
Schedule of Equity Method Investments [Line Items]                
Number of common shares held           2,989,414    
Percentage of investment           19.03%    
Hanmi Pharmaceuticals Co Ltd [Member] | Supply Agreement [Member]                
Schedule of Equity Method Investments [Line Items]                
Accrued liabilities     0   $ 0      
Accounts payable     $ 2,600,000   $ 2,600,000      
Maximum [Member] | Hanmi Pharmaceuticals Co Ltd [Member]                
Schedule of Equity Method Investments [Line Items]                
Investment for ownership interest               $ 7,000,000
Percentage of investment               19.99%